Michael Sofia
2022
In 2022, Michael Sofia earned a total compensation of $1.2M as Chief Scientific Officer at Arbutus Biopharma Corp, a 22% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $149,760 |
|---|---|
| Option Awards | $619,775 |
| Salary | $468,000 |
| Other | $10,675 |
| Total | $1,248,210 |
Sofia received $619.8K in option awards, accounting for 50% of the total pay in 2022.
Sofia also received $149.8K in non-equity incentive plan, $468K in salary and $10.7K in other compensation.
Rankings
In 2022, Michael Sofia's compensation ranked 2,606th out of 5,759 executives tracked by ExecPay. In other words, Sofia earned more than 54.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,606 out of 5,759 | 55th |
Division Manufacturing | 1,448 out of 3,135 | 54th |
Major group Chemicals And Allied Products | 658 out of 1,421 | 54th |
Industry group Drugs | 611 out of 1,322 | 54th |
Industry Pharmaceutical Preparations | 439 out of 968 | 55th |
Source: SEC filing on April 12, 2023.
Sofia's colleagues
We found two more compensation records of executives who worked with Michael Sofia at Arbutus Biopharma Corp in 2022.
News
Arbutus Biopharma Corp CEO William Collier's 2023 pay jumps 28% to $3.4M
April 10, 2024
Arbutus Biopharma Corp CEO William Collier's 2022 pay slips 18% to $2.6M
April 12, 2023
Arbutus Biopharma Corp CEO William Collier's 2021 pay rises 18% to $3.2M
April 11, 2022
Arbutus Biopharma Corp CEO William Collier's 2020 pay rises 17% to $2.7M
April 8, 2021
Arbutus Biopharma Corp CEO Mark Murray's 2019 pay jumps 50% to $3.8M
April 24, 2020